Otsuka Holdings Co.,Ltd.
  • For US customers
  • HOME
  • Japanese
  • About Our Group
  • News
  • Corporate Information
  • Financial Information
  • Research and Development
  • Social Responsibility
News
  • News Releases
  • 2010
  • 2009
  • 2008
  • Group Company News Releases
  • Otsuka Pharmaceutical Co.,Ltd.
  • 2010
  • 2009
  • 2008
  • Otsuka Pharmaceutical Factory,Inc.
  • 2009
  • Taiho Pharmaceutical Co.,Ltd.
  • 2009
  • Otsuka Chemical Co., Ltd.
  • 2009
HOME > Otsuka Pharmaceutical Co.,Ltd. News Releases

Otsuka Pharmaceutical Co.,Ltd. News Releases

RSS
23 Jul 2010

E Keppra® (levetiracetam) receives regulatory approval in Japan

12 Jul 2010

SPRYCEL® (dasatinib) Receives FDA Priority Review for the Treatment of Adult Patients with Newly Diagnosed Chronic Myeloid Leukemia (CML) in Chronic Phase

30 Jun 2010

GW and Otsuka Agree Three Year Extension
to Global Cannabinoid Research Collaboration

10 Jun 2010

Otsuka Pharmaceutical Co., Ltd. Appoints
the Board Members and Statutory Auditors (38KB)

9 Jun 2010

Four-Year Follow-Up Data for SPRYCEL® (dasatinib)Demonstrate 82 Percent Overall Survival
in Patients with Chronic Myeloid Leukemia Who Failed Gleevec®

8 Jun 2010

SPRYCEL® (dasatinib) Demonstrates Superior Confirmed Complete Cytogenetic
Response Rates Compared to Gleevec® in Study of Adult Patients with Newly Diagnosed
Chronic Myeloid Leukemia in Chronic Phase

7 Apr 2010

First reader-participation collaboration
OTSUKA Health Comic Library Sequel Vol. 3
“We Are Children of the Earth: The Environment & Our Health”
March 31 publication for donation to elementary schools nationwide

18 Mar 2010

Otsuka Pharmaceutical and Acucela Receive FDA Fast Track Designation for ACU-4429 in Patients with Dry AMD

1 Mar 2010

The Results of CSPS II, a Large-scale Clinical Trial of Cilostazol in Preventing Recurrent Strokes, Presented at American Stroke Association's International Stroke Conference on February 26

Back to top
  • Privacy Policy
  • Terms of Use
Copyright(C) 2009 Otsuka Holdings Co.,Ltd. All Rights Reserved.